Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05696613 · ClinicalTrials.gov registry record · Phase 3

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

A Phase 3 study of Primary Membranous Nephropathy, sponsored by Cerium Pharmaceuticals.

Recruiting
Registry status
Phase 3
Development phase
148
Enrollment target
20
Study locations

NCT05696613 is a Phase 3 study of Primary Membranous Nephropathy that is actively recruiting participants, run by Cerium Pharmaceuticals. The registered enrollment target is 148 participants, above the 118-participant average among 8 other Primary Membranous Nephropathy trials with a reported enrollment target (25% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05696613, a Phase 3 study of Primary Membranous Nephropathy, is actively recruiting participants, sponsored by Cerium Pharmaceuticals.

RECRUITING
Registry status
Phase 3
Development phase
148 participants
Enrollment target
20
Study locations

Study Summary

The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial. The goal of the Phase 3b part is to assess the efficacy of SNP-ACTH (1-39) Gel relative to rituximab in patients with primary membranous nephropathy (PMN) at month 24.

Conditions Studied

Primary Membranous Nephropathy

Interventions

  • DRUG Rituximab
  • DRUG SNP-ACTH (1-39) Gel

Study Locations (20)

Florida

  • RecioMed Clinical Research Network, Inc. - Boynton Beach
  • South Florida Nephrology Research - Coral Springs
  • Therafirst Medical Center - Fort Lauderdale
  • Reliant Medical Research, LLC - Miami
  • Vista Health Research, LLC - Miami
  • Genesis Clinical Research - Tampa

California

  • Academic Medical Research Institute - Los Angeles
  • North America Research Institute - San Dimas
  • Valiance Clinical Research - Tarzana

Georgia

  • Fides Clinical Research - Atlanta
  • Costal Medical Research - Brunswick

Texas

  • Prolato Clinical Research Center - Houston
  • P&I Clinical Research LLC - Lufkin

Virginia

  • University of Virginia - Charlottesville
  • Nephrology Associates of Northern Virginia - Fairfax

Illinois

  • Insight Hospital and Medical Center Chicago - Chicago

Iowa

  • University of Iowa - Iowa City

Michigan

  • Center for Advanced Kidney Research, PLC - Saint Clair Shores

Trial Details

FieldValue
Enrollment Target 148 participants
Start Date 2023-03-13
Est. Completion 2026-03-01
Phase Phase 3

Sponsor

Cerium Pharmaceuticals

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05696613

The ClinicalTrials.gov registry entry for NCT05696613 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 118-participant average among 8 other Primary Membranous Nephropathy trials with a reported enrollment target (25% higher). The listed sponsor is Cerium Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Primary Membranous Nephropathy appearing as the primary indexed condition, and to 2 interventions - of which Rituximab is the first listed.

NCT05696613 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT05696613 about?

NCT05696613 is a clinical study titled "A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy". The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial. The goal of the Phase 3b part is to assess the efficacy of SNP-ACTH (1-39) Gel relative to rituximab in patients with primary membranous nephropathy (P...

What is the current status of trial NCT05696613?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 148 participants. The study started on 2023-03-13. Estimated completion is 2026-03-01.

What conditions does trial NCT05696613 study?

This clinical trial studies the following conditions: Primary Membranous Nephropathy.

What interventions are being tested in trial NCT05696613?

The interventions under investigation include: Rituximab (DRUG), SNP-ACTH (1-39) Gel (DRUG).

Who is sponsoring clinical trial NCT05696613?

This trial is sponsored by Cerium Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05696613 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Primary Membranous Nephropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Primary Membranous Nephropathy

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.